Please assess the completion status of the following clinical trial:

Trial Title: Efficacy/Safety of Amlodipine Plus Losartan Versus Losartan in Patients With Essential Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients over 18 years of age~* Essential hypertensive patients whose blood pressure is not controlled before the study (sit DBP≥90 mmHg for drug-treated patient, sit DBP≥95mmHg for drug-naïve patient)~* Non-responder to 4 weeks treatment of losartan 100 mg monotherapy (sit DBP≥90mmHg)~Exclusion Criteria:~* mean sit SBP≥200mmHg or mean sit DBP≥120mmHg at screening~* mean sit SBP≥180 mmHg or mean sit DBP≥120mmHg after 4 weeks of losartan 100mg treatment~* has a history of hypersensitivity to dihydropyridines or angiotensin II receptor blockers~* Secondary hypertensive patient or suspected to be~* Uncontrolled diabetes mellitus patients~* Severe heart disease or severe neurovascular disease~* Known as severe or malignant retinopathy~* Patients showed clinically significant hematological finding, patients with renal diseases (serum creatinine), patients with hepatic disease (ALT or AST)~* History of malignancy tumor~* History of autoimmune disease~* History of alcohol or drug abuse~* Positive to pregnancy test, nursing mother, has an intention on pregnancy~* Considered by investigator as not appropriate to participate in the clinical study with othe reason

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- amlodipine/losartan 5/100mg (Type: EXPERIMENTAL): None
- losartan 100mg (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).